Success Metrics

Clinical Success Rate
85.7%

Based on 12 completed trials

Completion Rate
86%(12/14)
Active Trials
4(17%)
Results Posted
8%(1 trials)
Terminated
2(9%)

Phase Distribution

Ph not_applicable
1
4%
Ph phase_1
3
13%
Ph phase_2
10
43%
Ph phase_3
2
9%
Ph phase_4
5
22%

Phase Distribution

3

Early Stage

10

Mid Stage

7

Late Stage

Phase Distribution21 total trials
Phase 1Safety & dosage
3(14.3%)
Phase 2Efficacy & side effects
10(47.6%)
Phase 3Large-scale testing
2(9.5%)
Phase 4Post-market surveillance
5(23.8%)
N/ANon-phased studies
1(4.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

12 of 16 finished

Non-Completion Rate

25.0%

4 ended early

Currently Active

4

trials recruiting

Total Trials

23

all time

Status Distribution
Active(4)
Completed(12)
Terminated(4)
Other(3)

Detailed Status

Completed12
Recruiting3
unknown3
Withdrawn2
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
23
Active
4
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (14.3%)
Phase 210 (47.6%)
Phase 32 (9.5%)
Phase 45 (23.8%)
N/A1 (4.8%)

Trials by Status

recruiting313%
unknown313%
withdrawn29%
terminated29%
completed1252%
active_not_recruiting14%

Recent Activity

Clinical Trials (23)

Showing 20 of 23 trialsScroll for more
NCT07487675Phase 2

Evaluation of Intravenous Sodium Valproate on Interleukin-6 Levels in Patients With TMJ Disc Displacement

Active Not Recruiting
NCT05694936Phase 2

Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer

Recruiting
NCT07046676Phase 4

Pharmacogenetics-Based Study on Individualized Use of Sodium Valproate

Recruiting
NCT06393309

Levetiracetam Versus Valproate in Idiopathic Generalized Epilepsy

Completed
NCT06020898Phase 2

Sodium Valproate in Patients With Acute Ischemic Stroke

Recruiting
NCT06211283Phase 1

Bioavailability and Food Effect of Sodium Valproate Minitablets in Healthy Subjects.

Completed
NCT03825250Phase 1

The Val-CARD Trial

Unknown
NCT01730313Phase 2

Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda - 2012

Withdrawn
NCT03681158Phase 1

Study of Excretion Balance and Pharmacokinetics of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female Subjects

Completed
NCT03112889Phase 2

Sodium Valproate for GSDV

Completed
NCT00000439Phase 2

Drug Treatment for Alcoholics With Bipolar Disorder

Completed
NCT02920060Phase 2

Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus

Completed
NCT00713622Phase 4

Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate

Completed
NCT01619644Phase 2

Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial

Completed
NCT00139074Phase 4

Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients

Terminated
NCT00206778Phase 2

Six Month Trial of Lamotrigine vs. Sodium Valproate for Treatment of Mixed Mania

Completed
NCT00870688

Valproate Sustained Release Minitablets (Orfiril(R) Long) Once Daily in the Evening

Completed
NCT00153270Phase 4

Study of Efficacy of Sodium Valproate in Therapy of Bronchial Asthma

Completed
NCT00742638Not Applicable

To Evaluate the Efficiency and Safety of Quetiapine Fumarate in the Treatment of Acute Manic Patients With Bipolar Disorder.

Unknown
NCT00447369Phase 3

Efficacy of Pregabalin in Migraine Prevention

Withdrawn

Drug Details

Intervention Type
DRUG
Total Trials
23